Outcomes of Target Therapies for Paediatric BRAF V600-Mutant Low-Grade Gliomas: A systematic review and Meta-Analysis of Clinical and Observational Studies

Clicks: 4
ID: 322634
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #56 of 105 articles by views in Neuro-Oncology Advances

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background This systematic review and meta-analysis evaluated the efficacy, safety, and available functional outcomes of targeted therapies, including BRAF and MEK inhibitors, in paediatric patients with BRAF V600-mutant low-grade gliomas (pLGG). The review also explored their impact on clinical management, recovery, and quality of life. Methods The review followed PRISMA 2020 guidelines. Systematic searches were conducted across PubMed, ScienceDirect, EBSCO-hosted databases, and CENTRAL. Eligible studies included RCTs and retrospective studies (RS) reporting on tumour overall response rates (ORR), progression-free survival (PFS), adverse events (AEs), and functional outcomes in patients aged 1–17 years. Risk of bias was assessed using CASP; certainty of evidence with GRADE. Meta-analyses used a random-effects model (STATA 18.5). Funnel plots, Egger’s tests and subgroup/ sensitivity analyses explored bias and heterogeneity. Results Ten studies (16 treatment arms; 4 RCTS, 6 RS were included). Pooled ORR was 42.35% (95% CI: 29.41–55.29), and the median PFS was 23.03 months (95% CI: 17.18–28.88). Grade 3/4 AEs occurred in 30.56% (95% CI: 22.60–38.53), most commonly rash, fatigue, and fever. Subgroup analyses suggested higher efficacy and lower toxicity with BRAF inhibitors or combination therapy. Functional outcomes were inconsistently reported, though some evidence suggested improvements in vision and performance status. Conclusions Targeted therapies are effective and well tolerated in paediatric BRAF V600-mutant LGG, offering a promising alternative to chemotherapy, particularly in relapsed or progressive disease. Emerging evidence suggests potential benefit in selected molecularly defined patients, however further prospective studies are required to define their role in first-linetreatment. Standardised outcome reporting and long-term follow-up are essential to optimise care.
Reference Key
openalex_W7171405356 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Katherine Figueira, Laura Pigott
Journal Neuro-Oncology Advances
Year 2026
DOI
10.1093/noajnl/vdag192
URL
https://doi.org/10.1093/noajnl/vdag192
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.